Show simple item record

dc.contributor.advisorJiménez Cruz, Ronald Andrés,
dc.contributor.authorJaimes Vega, Nathalia Andreaspa
dc.contributor.authorJiménez Cruz, Ronald Andrésspa
dc.description76 páginas : gráficas, ilustracionesspa
dc.description.abstractEsta investigación busca analizar el aporte del Químico Farmacéutico en el desarrollo de productos de terapias avanzadas en Colombia, identificar los principales desafíos a nivel regulatorio para la implementación de productos de terapiasspa
dc.publisherBogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019spa
dc.rightsDerechos Reservados - Universidad de Ciencias Aplicadas y Ambientalesspa
dc.subject.meshCélulas Madrespa
dc.titleAporte del químico farmacéutico a los desafíos relacionados con el desarrollo de productos de terapias avanzadas en Colombiaspa
dc.typeTrabajo de grado - Pregradospa
dc.subject.lembQuímicos farmacéuticosspa
dc.description.notesIncluye bibliografíaspa
dc.identifier.localQF031 J13a 2019 (205833)spa
dc.relation.referencesAbbasalizadeh, S., & Baharvand, H. (2013). Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotechnology Advances, 31(8), 1600-1623.
dc.relation.referencesAnatol, R., Arcidiacono, J., Bailey, A. M., Durfor, C. N., Fink, D. W., Holobaugh, P., … Witten, C. (2014). The Regulatory Process from Concept to Market. Principles of Tissue Engineering (Fourth Edition). Elsevier.
dc.relation.referencesAtala, A. (2019). Principles of Tissue Engineering. Campbell-Walsh Urology (Eleventh E). Elsevier Inc.
dc.relation.referencesAusubel, Lara J. Lopez, P. M., & Couture, L. A. (2011). GMP Scale-Up and Banking of Pluripotent Stem Cells for Cellular Therapy Applications. Human Pluripotent Stem Cells, 767, 147-159spa
dc.relation.referencesAyala, L. A. (2007). Medicina regenerativa y enfermedades cardiovasculares: Terapia con células madre, 5(2),
dc.relation.referencesBaghbaderani, B. A., Tian, X., Neo, B. H., Burkall, A., Dimezzo, T., Sierra, G., … Rao, M. S. (2015). Stem Cell Reports. Stem Cell Reports, 5(4), 647-659.
dc.relation.referencesBall, O., Robinson, S., Bure, K. I. M., Brindley, D. A., & Mccall, D. (2018). Bioprocessing automation in cell therapy manufacturing : Outcomes of special interest group automation workshop. Cytotherapy, 20(4), 592-599.
dc.relation.referencesBravery, C. A., Carmen, J., Fong, T., Oprea, W., Hoogendoorn, K. H., Woda, J., … Hof, W. V. A. N. T. (2013). Potency assay development for cellular therapy products : an ISCT * review of the requirements and experiences in the industry. Journal of Cytotherapy, 15(1), 9-19.e9.
dc.relation.referencesBrien, F. J. O. (2011). Biomaterials & scaffolds for tissue engineering. Materials Today, 14(3), 88-95.
dc.relation.referencesBuckler, R. L. E. E., Kunkel, E. J., Thompson, M. L., & Ehrhardt, R. O. (2016). Technological developments for small-scale downstream processing of cell therapies. Cytotherapy, 18(3), 301-306.
dc.relation.referencesCalmels, B., Mfarrej, B., & Chabannon, C. (2018). From clinical proof-of-concept to commercialization of CAR T cells. Drug Discovery Today, 23(4), 758-762.
dc.relation.referencesCarreras, E. (2016). Guía del Trasplante de Médula Óseaspa
dc.relation.referencesChaparro, O., Ph, D., Beltrán, O., & Sc, M. (2009). REPROGRAMACIÓN NUCLEAR Y CÉLULAS Introducción. Med, 17(2),
dc.relation.referencesCorbett, M. S., Webster, A., Hawkins, R., & Woolacott, N. (2017). Innovative regenerative medicines in the EU : a better future in evidence ?, 1-8.
dc.relation.referencesCuende, N., Rasko, J. E. J., & Koh, M. B. C. (2018). Cell , tissue and gene products with marketing authorization in 2018 worldwide. Cytotherapy, 20(11), 1401- 1413.
dc.relation.referencesDetela, G., & Lodge, A. (2016). Manufacturing process development of ATMPs within a regulatory framework for EU clinical trial & marketing authorisation applications. Cell and gene therapy insights, 425-452.
dc.relation.referencesDeusen, A. L. Van. (2016). 6 - Compatibility of GxP with Existing Cell Therapy Quality Standards. Guide to Cell Therapy GxP. Elsevier Inc.
dc.relation.referencesDotti, G., & Brenner, M. K. (2019). Chapter 100 - T-Cell Therapy of Hematologic Diseases. En Hematology (Seventh Ed, pp. 1568-1574). Elsevier Inc.
dc.relation.referencesDuvall, C. L., Gersbach, C. A., & Davidson, J. M. (2014). Gene Delivery into Cells and Tissues.
dc.relation.referencesEaker, S., Abraham, E., Allickson, J., Brieva, T. A., Baksh, D., Heathman, T. R. J., … Zhang, N. A. N. (2017). Bioreactors for cell therapies : Current status and future advances. Cytotherapy, 19(1), 9-18.
dc.relation.referencesFernández Collado, C., & Baptista Lucio, P. (2014). Metodología de la Investigación. (McGrawHill, Ed.) (6a ed.). México,
dc.relation.referencesFoss, D. V, Hochstrasser, M. L., & Wilson, R. C. (2018). Clinical applications of CRISPR-based genome editing and diagnostics. Transfusion, 0, 1-11.
dc.relation.referencesFreimark, D., Pino-Grace, P.-, Pohl, S., Weber, C., Wallrapp, C., & Geigle, P. (2010). Use of encapsulated stem cells to overcome the bottleneck of cell availability for cell therapy approaches. Transfusion Medicine Hemotherapy, 37,
dc.relation.referencesFundación Mencía. (2017). Fundación Mencía. Recuperado a partir de
dc.relation.referencesFurth, M. E., Atala, A., Innovations, W. F., & Carolina, N. (2014). Tissue Engineering : Future Perspectives. Principles of Tissue Engineering (Fourth Edition). Elsevier.
dc.relation.referencesGarcía, S. C. (2012). Gen ajeno o exógeno : transgén, 4,
dc.relation.referencesGavin, D. K., & Ph, D. (s. f.). Advanced Topics : Successful Development of Quality Cell and Gene Therapy Products Division of Cellular and Gene
dc.relation.referencesGee, A. P. (2009). Cell therapy: cGMP Facilities and Manufacturing. (A. P. Gee, Ed.) (1.a ed.). Houston, TX: Springer US.
dc.relation.referencesGee, A. P. (2019). Chapter 97 - Graft Engineering and Cell Processing. Hematology (Seventh Ed). Elsevier Inc. 4spa
dc.relation.referencesGilbert, T. W., Sellaro, T. L., & Badylak, S. F. (2006). Decellularization of tissues and organs. Biomaterials, 27, 3675-3683.
dc.relation.referencesGuzmán Cruz, J. H., & Otálvaro Cifuentes, E. H. (2016). PERSPECTIVA DE TERAPIAS AVANZADAS EN EL MARCO NORMATIVO. Cartagena:
dc.relation.referencesHernández Ramírez, P. (2006). Medicina regenerativa II. Aplicaciones, realidad y perspectivas de la terapia celular. Revista Cubana de Hematología, Inmunología y Hemoterapia, 22(1). Recuperado a partir de 02892006000100002spa
dc.relation.referencesHildebrand, M., & Hochschule, M. (2011). Manufacture of advanced therapies : Academia meets industry, 8(7), 9-10spa
dc.relation.referencesHouse of Lords Science and Technology Committee. (2013). Regenerative medicine report.
dc.relation.referencesHuman, T. H. E., Stem, E., Human, T. H. E., & Germ, E. (1998). THE HUMAN EMBRYONIC STEM CELL AND, 11-22spa
dc.relation.referencesIglesias-lópez, C., Agustí, A., Obach, M., & Vallano, A. (2019). Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States, 10(August), 1-14.
dc.relation.referencesIyer, R. K., Bowles, P. A., Kim, H., & Dulgar-tulloch, A. (2018). Industrializing Autologous Adoptive Immunotherapies : Manufacturing Advances and Challenges, 5(May), 1-9.
dc.relation.referencesJones, J. (2005). Scaffolds for tissue engineering. En Biomaterials, artificial organs and tissue engineering (pp. 201-214).
dc.relation.referencesKalra, K., & Tomar, P. C. (s. f.). Stem Cell : Basics , Classification and Applicationsspa
dc.relation.referencesKarginov, F., & Hannon, G. (2010). The CRISPR System: Small RNA-Guided Defense in Bacteria and Archaea Molecular Cell. Molecular Cell, 37(1), 7-19.
dc.relation.referencesKhademhosseini, A., Karp, J. M., Gerecht-nir, S., Ferreira, L., Annabi, N., Sirabella, D., & Vunjak-novakovic, G. (2014). Embryonic Stem Cells as a Cell Source for Tissue Engineering. Principles of Tissue Engineering (Fourth Edition). Elsevier.
dc.relation.referencesKulinets, I. (2015). Biomaterials and their applications in medicine. En Regulatory Affairs for Biomaterials and Medical Devices (pp. 1-10). Woodhead Publishing Limited.
dc.relation.referencesLindblad, R., Mondoro, T. H., & Wood, D. (2019). INVESTIGATIONAL NEW DRUG – ENABLING PROCESSES FOR CELL-BASED THERAPIES. Hematology (Seventh Ed). Elsevier Inc. 35762-3.00096-2spa
dc.relation.referencesLowry, W. E., & Quan, W. L. (2010). Roadblocks en route to the clinical application of induced pluripotent stem cells. Journal of Cell Science, 123,
dc.relation.referencesMa, R., Schaer, M., Hogan, M., Demange, M., & Rodeo, S. A. (2019). Orthobiologics : Clinical Application of Platelet-Rich Plasma and Stem Cell Therapy. DeLee, Drez, and Miller’s Orthopaedic Sports Medicine (Fourth Edi). Elsevier Inc.
dc.relation.referencesManuscript, A. (2013). NIH Public Access, 18(3), 217-222.
dc.relation.referencesMaría, D., & Ibarz, T. (s. f.). Desafíos en la Regulación de Nuevos Productos Biológicos : Terapia Génica , Celular y Tisular Terapia Génica , Celular y Tisular Estrategias terapéuticas innovadoras que ofrecen nuevas oportunidades para algunas enfermedades que carecen
dc.relation.referencesMarketsandMarkets. (2019). Regenerative Medicine Market by Type. USspa
dc.relation.referencesMartin, G. (1981). Isolation of a pluripoten cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl Acad. Sci. USA,
dc.relation.referencesMartin, U. (2017). Therapeutic Application of Pluripotent Stem Cells : Challenges and Risks, 4(December).
dc.relation.referencesMason, C., & Brindley, D. A. (2011). Cell therapy industry : billion dollar global business with unlimited potential E ditorial. Regenerative Medicine, 6(3), 265- 272spa
dc.relation.referencesMoffat, K. L., Neal, R. A., Freed, L. E., & Guilak, F. (2014). Engineering Functional Tissues : In Vitro Culture Parameters. Principles of Tissue Engineering (Fourth Edition). Elsevier.
dc.relation.referencesMorrow, D., Ussi, A., & Migliaccio, G. (2017). Addressing Pressing Needs in the Development of Advanced therapies, 5(September), 1-6.
dc.relation.referencesMulet, J., & Cance, P. (s. f.). Development of Advanced Therapy Medicinal Products in Europe. BlueReg Pharma Consultingspa
dc.relation.referencesNaldini, L. (2011). Ex vivo gene transfer and correction for cell-based therapies. Nature Publishing Group, 12(5), 301-315.
dc.relation.referencesNational Institue of Health. (2019). Clinical Trials. Recuperado a partir de
dc.relation.referencesNIH. (s. f.). Recuperado a partir de
dc.relation.referencesNIH, N. I. of H. (2015). Stem Cell
dc.relation.referencesOliveira, E. P., Silva-correia, J., & Reis, R. L. (2018). Biomaterials Developments for Brain Tissue
dc.relation.referencesOsorio-Delgado, M. A., Henao-Tamayo, L. J., Velásquez-Cock, J. A., CañasGutiérrez, A. I., Restrepo-Múnera, L. M., Gañán-Rojo, P. F., … Castro-Herazo, C. I. (2017). Biomedical applications of polymeric biomaterials • Aplicaciones biomédicas de biomateriales poliméricos. DYNA, 84(201), 241-252.
dc.relation.referencesPereira, T. D., Moncaubeig, F., & Farid, S. S. (2018). Impact of allogeneic stem cell manufacturing decisions on cost of goods , process robustness and reimbursement. Biochemical Engineering Journal, 137, 132-151.
dc.relation.referencesPicó, Y., Farré, M., Kantiani, L., & Barceló, D. (2012). Microfluidic Devices: Biosensors. Chemical Analysis of Food: Techniques and Applications, 177-217.
dc.relation.referencesResearch and Markets. (2019). Global Market for Cell Therapy & Tissue Engineering 2019. Recuperado a partir de &utm_campaign=1240202+- +Global+Market+for+Cell+Therapy+%26+Tissue+Engineering%2C+2019%3A +The+Arrival+of+Regenerative+Medicine+(RM)+has+been+Propelled+by+Ad vances+Across+the+Cell+Therapy+(CT)+and+Tissue+(TE)+Engineering+Indus tries&utm_exec=joca220prdspa
dc.relation.referencesRoa Ramirez, Derly Alexandra; Quitian Ayala, R. del P. (2016). SITUACIÓN ACTUAL DE LA INGENIERIA DE TEJIDOS Y MEDICINA REGENERATIVA EN COLOMBIA. Universidad de Ciencias Aplicadas y Ambientales (UDCA).spa
dc.relation.referencesRodríguez, E. D. E. D., Peña, A. V., Edreira, A. R., García, B. M., Infiesta, A. M., & Llames, S. G. (2004). ESTADO ACTUAL DE LA INGENIERIA DE TEJIDOS EN UROLOGÍA. REVISIÓN DE LA LITERATURA. Actas Urológicas Españolas, 28(9),
dc.relation.referencesScienceDirect. (s. f.). Recuperado a partir de
dc.relation.referencesSlack, J. M. W. (2014). Molecular Biology of the Cell. Principles of Tissue Engineering (Fourth Edition). Elsevier. 398358-9.00007-0spa
dc.relation.referencesSolomon, J., Csontos, L., Clarke, D., Bonyhadi, M., Zylberberg, C., Mcniece, I. A. N., … Deans, R. (2016). Current perspectives on the use of ancillary materials for the manufacture of cellular therapies. Cytotherapy, 18(1), 1-12.
dc.relation.referencesSpector, M. (2006). Biomaterials-based tissue engineering and regenerative medicine solutions to musculoskeletal problems. Swiss Med Wkly, 136,
dc.relation.referencesStockdale, F. E. (2014). Gene Expression , Cell Determination , and Differentiation. Principles of Tissue Engineering (Fourth Edition). Elsevier.
dc.relation.referencesSuárez, J., & Herreros, D. L. (s. f.). Tratamiento Regenerativo en Pacientes con Infarto de Miocardio Anterior Extenso con Infarto de Miocardio Anterior Extenso Tratamiento Regenerativo en
dc.relation.referencesTakebe, T., Sekine, K., Kimura, M., Yoshizawa, E., Ayano, S., Koido, M., … Taniguchi, H. (2017). Massive and Reproducible Production of Liver Buds Entirely from Human Pluripotent Stem Cells Report Massive and Reproducible Production of Liver Buds Entirely from Human Pluripotent Stem Cells. CellReports, 21(10), 2661-2670.
dc.relation.referencesTakeda, H., Dondzillo, A., Randall, J. A., & Gubbels, S. P. (2019). Challenges in Cell-Based Therapies for the Treatment of Hearing Loss. Trends in Neurosciences, 41(11), 823-837.
dc.relation.referencesTavira Montalván, C. A., Ortega García, A., Dávila González, I., Estrada Moncada, S., & Meneses Acosta, A. (2009). Alcances y perspectivas del cultivo de células animales en la biotecnología farmacéutica Animal cell culture in pharmaceutical biotechnology : research and perspectives. Revista Mexicana de Ciencias Farmacéuticas, 40(4).spa
dc.relation.referencesU.S Department of Health and Human Services. (2019). National Institutes of Health Recuperado a partir de
dc.relation.referencesUnited States Adopted Names. (2016). American Medical Association. Recuperado a partir de
dc.relation.referencesWorgall, S., & Crystal, R. G. (2014). Gene Therapy. Principles of Tissue Engineering (Fourth Edition). Elsevier.
dc.relation.referencesYu, J., & Thomson, J. A. (2001). 1. embryonic stem cells,
dc.relation.referencesZafar, M. S., Ullah, R., Qamar, Z., Fareed, M. A., Amin, F., Khurshid, Z., & Sefat, F. (2019). Properties of dental biomaterials. En F. S. Zohaib Khurshid, Shariq Najeeb, Muhammad Sohail Zafar (Ed.), Advanced Dental Biomaterials (1.a ed., pp. 7-35). Woodhead Publishing Limited.
dc.relation.referencesZakrzewski, W., Dobrzy, M., Szymonowicz, M., & Rybak, Z. (2019). Stem cells : past , present , and future, 5,
dc.relation.referencesZhou, W., & Kantardjieff, A. (s. f.). Mammalian Cell Cultures for Biologics
dc.rights.creativecommonsAtribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)spa
dc.description.degreenameQuímico(a) Farmacéuticospa
dc.publisher.facultyFacultad de Cienciasspa
dc.publisher.programQuímica Farmacéuticaspa

Files in this item


This item appears in the following Collection(s)

Show simple item record

Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales
Except where otherwise noted, this item's license is described as Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales